MA27387A1 - PRECURSEUR DE MEDICAMENT INHIBITEUR DE BeTA-LACTAMASE - Google Patents

PRECURSEUR DE MEDICAMENT INHIBITEUR DE BeTA-LACTAMASE

Info

Publication number
MA27387A1
MA27387A1 MA28119A MA28119A MA27387A1 MA 27387 A1 MA27387 A1 MA 27387A1 MA 28119 A MA28119 A MA 28119A MA 28119 A MA28119 A MA 28119A MA 27387 A1 MA27387 A1 MA 27387A1
Authority
MA
Morocco
Prior art keywords
beta
solvates
mammal
present
drug precursor
Prior art date
Application number
MA28119A
Other languages
English (en)
Inventor
Anthony Marfat
Dale Gordon Mcleod
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27387A1 publication Critical patent/MA27387A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Précurseur de médicament inhibiteur de bêta-lactamase Des précurseurs médicamenteux de sulfone d'acide 6-(bêta)-hydroxyméthylpénicillanique ayant la structure dans laquelle R représente H ou un groupe méthyle, et leurs produits de solvatation sont décrits. Il est décrit également des compositions pharmaceutiques comprenant un précurseur médicamenteux de la présente invention, ou un de ses produits de solvatation, un antibiotique bêta-lactame facultatif et au moins un support pharmaceutiquement acceptable. Il est décrit en outre une méthode pour accroître l'efficacité thérapeutique d'un antibiotique bêta-lactame chez un mammifère en administrant une quantité efficace d'antibiotique bêta-lactame et une quantité, à effet d'augmentation d'efficacité, d'un précurseur médicamenteux de la présente invention ou d'un de ses produits de solvatation. Il est décrit en outre une méthode pour le traitement d'une infection bactérienne chez un mammifère en administrant une quantité thérapeutiquement efficace d'une composition pharmaceutique de la présente invention à un mammifère nécessitant un tel traitement.
MA28119A 2002-08-23 2005-02-23 PRECURSEUR DE MEDICAMENT INHIBITEUR DE BeTA-LACTAMASE MA27387A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40564002P 2002-08-23 2002-08-23

Publications (1)

Publication Number Publication Date
MA27387A1 true MA27387A1 (fr) 2005-06-01

Family

ID=31946909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28119A MA27387A1 (fr) 2002-08-23 2005-02-23 PRECURSEUR DE MEDICAMENT INHIBITEUR DE BeTA-LACTAMASE

Country Status (31)

Country Link
US (1) US7091197B2 (fr)
EP (1) EP1534717B1 (fr)
JP (1) JP2005539037A (fr)
KR (1) KR20050037583A (fr)
CN (1) CN1688589A (fr)
AP (1) AP2005003231A0 (fr)
AR (1) AR041028A1 (fr)
AT (1) ATE349452T1 (fr)
AU (1) AU2003250489A1 (fr)
BR (1) BR0313683A (fr)
CA (1) CA2494953A1 (fr)
DE (1) DE60310733D1 (fr)
EA (1) EA007540B1 (fr)
EC (1) ECSP055625A (fr)
GT (1) GT200300179A (fr)
HR (1) HRP20050162A2 (fr)
IL (1) IL166719A0 (fr)
IS (1) IS7693A (fr)
MA (1) MA27387A1 (fr)
MX (1) MXPA05001446A (fr)
NO (1) NO20051497L (fr)
NZ (1) NZ538340A (fr)
OA (1) OA12909A (fr)
PA (1) PA8579701A1 (fr)
PE (1) PE20040899A1 (fr)
PL (1) PL375988A1 (fr)
TN (1) TNSN05054A1 (fr)
TW (1) TWI250162B (fr)
UY (1) UY27947A1 (fr)
WO (1) WO2004018484A1 (fr)
ZA (1) ZA200501513B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526612A (ja) * 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
WO2007012319A1 (fr) * 2005-07-29 2007-02-01 Sigma-Aldrich Production Gmbh Melanges lc/ms contenant des additifs ionisants
WO2010118968A1 (fr) 2009-04-16 2010-10-21 Nicox S.A. Dérivés d'aspirine donneurs de no
WO2013056163A1 (fr) 2011-10-14 2013-04-18 The Regents Of The University Of California Inhibiteurs de bêta-lactamase
JP2015506360A (ja) * 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34011B1 (en) * 1969-03-13 1975-01-08 Leo Pharm Prod Ltd New penicillin esters
IE34019B1 (en) * 1969-03-18 1975-01-08 Leo Pharm Prod Ltd New semi-synthetic penicillin esters
GB1267936A (en) 1969-05-28 1972-03-22 Beecham Group Ltd DERIVATIVES OF alpha-AMINOPENICILLINS
US3957764A (en) * 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
US3862181A (en) * 1970-10-28 1975-01-21 Squibb & Sons Inc Process for preparing cephalosporins
GB1315566A (en) 1970-11-06 1973-05-02 Leo Pharm Prod Ltd Penicillanic acid derivatives
CA996929A (en) 1971-04-05 1976-09-14 Kohzi Nakano Acyloxyalkyl ester derivatives of penicillin
GB1426717A (en) 1972-03-13 1976-03-03 Astra Laekemedel Ab Penicillins
GB1433131A (en) * 1972-03-13 1976-04-22 Astra Laekemedel Ab Penicillins
US4397783A (en) * 1979-03-05 1983-08-09 Pfizer Inc. Process for converting 6,6-disubstituted penicillanic acid derivatives to the 6-β-congeners
DE2927004A1 (de) * 1979-07-04 1981-05-27 Bayer Ag, 5090 Leverkusen Penicillansaeure-1,1-dioxide, ihre herstellung und ihre verwendung als arzneimittel als arzneimittel
US4287181A (en) * 1979-10-22 1981-09-01 Pfizer Inc. Derivatives of 6β-hydroxyalkylpenicillanic acids as β-lactamase inhibitors
US4432970A (en) * 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
GB2076812A (en) * 1980-05-22 1981-12-09 Ciba Geigy Ag Penam-dioxide compounds, processes for their manufacture, and their use
JPS5849387A (ja) 1981-09-17 1983-03-23 Sankyo Co Ltd ７−メトキシセフアロスポリン化合物およびその製法
AU559689B2 (en) * 1981-09-22 1987-03-19 Kureha Kagaku Kogyo K.K. Penicillin derivative
US4406887A (en) * 1981-10-13 1983-09-27 Bristol-Myers Company Method for treating resistant bacteria including anaerobes
US4428935A (en) * 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US4521533A (en) * 1984-07-12 1985-06-04 Pfizer Inc. Salts of 6-alpha-(aminomethyl)penicillanic acid 1,1-dioxide esters and beta-lactam antibiotics
DE3901405A1 (de) 1989-01-19 1990-07-26 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
JPH03206038A (ja) 1990-01-08 1991-09-09 Yoshitomi Pharmaceut Ind Ltd 抗菌剤
GB9001405D0 (en) * 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
JP2006526612A (ja) * 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ

Also Published As

Publication number Publication date
EP1534717B1 (fr) 2006-12-27
UY27947A1 (es) 2004-03-31
BR0313683A (pt) 2005-06-21
PL375988A1 (en) 2005-12-12
US20040110740A1 (en) 2004-06-10
CN1688589A (zh) 2005-10-26
IS7693A (is) 2005-02-10
ATE349452T1 (de) 2007-01-15
JP2005539037A (ja) 2005-12-22
EA200500398A1 (ru) 2005-08-25
PA8579701A1 (es) 2005-05-24
AU2003250489A1 (en) 2004-03-11
IL166719A0 (en) 2006-01-15
ZA200501513B (en) 2006-09-27
EP1534717A1 (fr) 2005-06-01
DE60310733D1 (de) 2007-02-08
NO20051497D0 (no) 2005-03-21
EA007540B1 (ru) 2006-10-27
TWI250162B (en) 2006-03-01
AR041028A1 (es) 2005-04-27
TNSN05054A1 (fr) 2007-05-14
NZ538340A (en) 2006-10-27
CA2494953A1 (fr) 2004-03-04
PE20040899A1 (es) 2004-12-28
WO2004018484A1 (fr) 2004-03-04
HRP20050162A2 (en) 2005-06-30
AP2005003231A0 (en) 2005-03-31
ECSP055625A (es) 2005-04-18
KR20050037583A (ko) 2005-04-22
MXPA05001446A (es) 2005-06-06
NO20051497L (no) 2005-03-21
TW200417548A (en) 2004-09-16
US7091197B2 (en) 2006-08-15
OA12909A (en) 2006-10-13
GT200300179A (es) 2004-05-18

Similar Documents

Publication Publication Date Title
Jolivet-Gougeon et al. Antimicrobial treatment of Capnocytophaga infections
JP7617179B2 (ja) 安定したアスコルビン酸組成物およびそれを使用する方法
DK1879655T3 (en) Pharmaceutical composition comprising an antibacterial agent and an active substance selected from carveol, carvacrol, alpha-ionone, beta-ionone, and thymol
US11324715B2 (en) Bismuth-thiol compositions and methods for treating wounds
Hirai et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori
EP0222834A1 (fr) Traitement de la dyspepsie non ulcereuse avec des sels de bismuth
WO2001054681A8 (fr) Composition anti-stress
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
ATE246192T1 (de) Ethyliden-derivate tricyclyscher carbapenems
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
TNSN05054A1 (fr) Precurseur de medicament inhibiteur de beta-lactamase
EP0437128B1 (fr) Utilisation des dérivés des fluoroquinolones pour le traitement de la pneumonie à Pneumocystis carinii
Neu Infections due to gram-negative bacteria: an overview
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DZ1324A1 (fr) Dérivés de céphalosporine, procédé pour leur préparation compositions pharmaceutiques les contenant et leur utilisation dans le traitement d'infections bactériennes.
EP2260870A2 (fr) Traitement de maladies infectieuse par des mélanges de dérivés de thioxanthène avec des agents anti-infectieux
MA26744A1 (fr) Polymorphes d'un chlorhydrate d'azo-bicyclo-2,2,2-oct-3-ylamine cristallins et compositions pharmaceutiques les contenant
Ruben Rothia dentocariosa endocarditis
JP2006504404A5 (fr)
Schwalm et al. Clinical outcome with oral linezolid and rifampin following recurrent methicillin‐resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment
EP1389120B1 (fr) Utilisation de la nystatine pour le traitement de l'athérosclérose liée à la présence de champignons parasites
Gurzhenko et al. SYSTEMIC ENZYME THERAPY DRUGS IN THE TREATMENT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES OF THE MALE GENITAL ORGANS
MALININ et al. Biliary concentrations of cefamandole and its use in biliary tract surgery
WO2025083393A1 (fr) Utilisation antimicrobienne de peptides dérivés de l'annexine a1
EP0495721B1 (fr) Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des pneumothorax